Deuterium-enriched hyaluronan

Abstract

The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same.

What is claimed is: 
     
       1. A topical anti-wrinkle and anti-aging moisturizing composition, comprising: a d-HA of the formula: 
       
         
           
           
               
               
           
         
         or a cosmetically acceptable salt thereof, wherein: 
         the d-HA has a molecular weight selected from about 15 kDa to about 10 MDa; and, 
         each R D  and R D1  is independently hydrogen or deuterium, provided that at least 1% of the total number of R D  and R D1  groups present are D; 
         and a cosmetically acceptable excipient; 
         wherein the composition is in the form, selected from: a cream, ointment, gel, serum, hydrogel patch, and liposome preparation. 
       
     
     
       2. The composition of  claim 1 , wherein the d-HA is of formula d-HA1: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein: 
         each R D1  is independently hydrogen or deuterium, provided that at least 1% of the R D1  groups present are D. 
       
     
     
       3. The composition of  claim 1 , wherein the d-HA is of formula d-HA B1 : 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein: 
         each R D1  is independently hydrogen or deuterium, provided that at least 1% of the R D1  groups present are D. 
       
     
     
       4. The composition of  claim 1 , wherein the d-HA is of formula F: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
       5. The composition of  claim 1 , wherein the d-HA is of formula d-HA 2 : 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein: 
         each R D  is independently hydrogen or deuterium, provided that at least 1% of the R D  groups present are D. 
       
     
     
       6. The composition of  claim 1 , wherein the molecular weight of the d-HA is selected from about 0.1 MDa to about 5 MDa. 
     
     
       7. The composition of  claim 1 , wherein the molecular weight of the d-HA is selected from about 0.5 MDa to about 3 MDa. 
     
     
       8. The composition of  claim 1 , wherein the molecular weight of the d-HA is about 1-2.5 MDa. 
     
     
       9. The composition of  claim 1 , wherein the molecular weight of the d-HA is selected from about 15 kDa to about 100 kDa. 
     
     
       10. The composition of  claim 1 , wherein the molecular weight of the d-HA is selected from about 15 kDa to about 35 kDa. 
     
     
       11. The composition of  claim 1 , wherein at least 5% of the total number of R D  and/or R D1  groups present are D. 
     
     
       12. The composition of  claim 1 , wherein at least 10% of the total number of R D  and/or R D1  groups present are D. 
     
     
       13. The composition of  claim 1 , wherein at least 20% of the total number of R D  and/or R D1  groups present are D. 
     
     
       14. The composition of  claim 1 , wherein at least 30% of the total number of R D  and/or R D1  groups present are D. 
     
     
       15. The composition of  claim 1 , wherein at least 40% of the total number of R D  and/or R D1  groups present are D. 
     
     
       16. The composition of  claim 1 , wherein at least 50% of the total number of R D  and/or R D1  groups present are D. 
     
     
       17. The composition of  claim 1 , wherein at least 60% of the total number of R D  and/or R D1  groups present are D. 
     
     
       18. The composition of  claim 1 , wherein at least 70% of the total number of R D  and/or R D1  groups present are D. 
     
     
       19. The composition of  claim 1 , wherein at least 80% of the total number of R D  and/or R D1  groups present are D. 
     
     
       20. The composition of  claim 1 , wherein at least 90% of the total number of R D  and/or R D1  groups present are D. 
     
     
       21. The composition of  claim 1 , wherein the composition is in the form of a hydrogel patch. 
     
     
       22. The composition of  claim 21 , wherein the hydrogel patch is suitable for iontophoretic delivery of the d-HA into the skin. 
     
     
       23. The composition of  claim 1 , wherein the composition is in the form of a liposomal preparation. 
     
     
       24. The composition of  claim 23 , further comprising: skin-penetrating peptides for delivery of the d-HA into the skin. 
     
     
       25. The composition of  claim 1 , wherein the cosmetically acceptable excipient is a cosmetically acceptable peptide or transdermal delivery facilitating agent.